BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

iTraumaCare Receives European Union CE Marking for iTClamp™ Hemorrhage Control System


3/21/2013 9:03:27 AM

SAN ANTONIO--(BUSINESS WIRE)-- iTraumaCare, an early-stage medical device firm focused on developing traumatic injury solutions for first responder and military medicine applications, has achieved its second regulatory milestone. The company received CE Mark approval to market its first product, the iTClampTM Hemorrhage Control System, in participating European Union countries. The product, which was licensed for sale in Canada in late 2012, will be available to medical professionals in participating European Union countries within 30 to 45 days.

The iTClamp is designed to address massive hemorrhage – a leading cause of death in traumatic injury – by controlling critical bleeding in seconds. The iTClamp seals the edges of a wound closed to create a temporary pool of blood under pressure, which forms a stable clot that mitigates further blood loss until the wound can be surgically repaired.

CE Mark approval is a key indicator of a product's compliance with EU legislation and enables the free movement of products within the European market. This CE Mark approval applies to the use of the iTClamp Hemorrhage Control System in participating European Union countries only and does not apply in the US. The company expects US clearance of the iTClamp from the FDA in 2013.

iTraumaCare’s CEO and founder, Dr. Dennis Filips, said, “We are delighted with the rapid acceptance of the iTClamp and look forward to launching in Europe soon.”

Incorporated in 2010 and based in Edmonton, Canada with a global commercialization headquarters in San Antonio, Texas, iTraumaCare is addressing unmet needs in the field of emergency medicine by developing, manufacturing, and commercializing solutions to treat common causes of preventable death in traumatic injury scenarios.

Contact:

for iTraumaCare

Lisa Owens, 210-601-6647

lisaowens@regval.com



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES